ASCO News In Brief: Hoechst Marion Roussel Anzemet
Executive Summary
Hoechst Marion Roussel Anzemet: Oral dolasetron mesylate for prevention of acute nausea and vomiting after moderately emetogenic platinum-containing chemotherapy may be optimal at 200 mg dose, according to dose-response data from a 307-patient trial presented at the American Society of Clinical Oncology meeting in Philadelphia May 18-21. The drug is administered 30 minutes prior to chemotherapy. A complete response rate of 73% was reported in the 200 mg dolasetron arm, compared to a 40% CR in the 25 mg arm; 61% of patients receiving 200 mg had no nausea versus 35% of those receiving 25 mg. An NDA for Anzemet was submitted in April...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth